Cost-effectiveness analysis of Chaiyin Granules in treatment of influenza.
10.19540/j.cnki.cjcmm.20230323.501
- Author:
Li-Man DING
1
;
Dao-Wen YANG
2
;
Hong-Chun ZHANG
2
;
Xiao MA
3
;
Zhen-Gang YAN
4
;
Sheng-Tang ZHANG
5
;
Wu-Zhi MA
6
;
Wei-Ge LI
7
;
Dong-Xing WU
8
;
Qing-Rong JIANG
9
Author Information
1. Zhejiang Chinese Medical University Hangzhou 310053,China.
2. China-Japan Friendship Hospital Beijing 100029,China.
3. Luohe Hospital of Traditional Chinese Medicine Luohe 462000,China.
4. the First People's Hospital of Tancheng Linyi 276100,China.
5. the People's Hospital of Linqing Linqing 252600,China.
6. Nanning Tenth People's Hospital Nanning 530105,China.
7. Guanxian Hospital of Traditional Chinese Medicine Liaocheng 252599,China.
8. the People's Hospital of Guantao County Handan 057750,China.
9. Chiping District Hospital of Traditional Chinese Medicine in Liaocheng City Liaocheng 252199,China.
- Publication Type:Journal Article
- Keywords:
Chaiyin Granules;
Chinese patent medicine;
Oseltamivir Phosphate Capsules;
cost-effectiveness analysis;
influenza
- MeSH:
Humans;
Antipyretics/therapeutic use*;
Antiviral Agents/therapeutic use*;
Cost-Effectiveness Analysis;
Influenza, Human/drug therapy*;
Nucleic Acids/therapeutic use*;
Oseltamivir/therapeutic use*;
Phosphates/therapeutic use*;
Treatment Outcome;
Double-Blind Method
- From:
China Journal of Chinese Materia Medica
2023;48(16):4529-4535
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to evaluate the cost-effectiveness of Chaiyin Granules compared with Oseltamivir Phosphate Capsules in the treatment of influenza(exogenous wind-heat syndrome). Based on a randomized, double-blind, positive drug parallel control clinical trial, this study evaluated the pharmacoeconomics of Chaiyin Granules with cost-effectiveness analysis method. A total of 116 patients with influenza from eight hospitals(grade Ⅱ level A above) in 6 cities were selected in this study, including 78 cases in the experimental group with Chaiyin Granules and Oseltamivir Phosphate Capsules placebo, and 38 cases in the control group with Oseltamivir Phosphate Capsules and Chaiyin Granules placebo. The total cost of this study included direct medical cost, direct non-medical cost, and indirect cost. The remission time of clinical symptoms, cure time/cure rate, antipyretic onset time/complete antipyretic time, viral nucleic acid negative rate, and traditional Chinese medicine(TCM) syndrome curative effect were selected as the effect indicators for cost-effectiveness analysis. Four-quadrant diagram was used to estimate the incremental cost-effectiveness ratio. The results showed that Chaiyin Granules were not inferior to Oseltamivir Phosphate Capsules in the remission time of clinical symptoms of influenza(3.1 d vs 2.9 d, P=0.360, non-inferiority margin was 0.5 d). Compared with Oseltamivir Phosphate Capsules, Chaiyin Granules would delay the remission time of clinic symptoms of influenza for 1 d, but could save 213.9 yuan. 1 d delay in cure time could save 149.3 yuan; 1% reduction in the cure rate could save 8.2 yuan; 1 d delay in antipyretic onset time could save 295.4 yuan; 1 d delay in complete antipyretic time could save 114.3 yuan; 1% reduction in the 5-day cure rate of TCM syndrome could save 19.2 yuan. Different from other indicators, there was no statistically significant difference between two groups in the effect of negative conversion rate of viral nucleic acid, but the cost was lower and the effect was superior, and the pharmacoeconomics was not different from that of Oseltamivir Phosphate Capsules in the field of influenza treatment.
